{‘She lacks little experience’: the US healthcare field girds for Høeg's role at the FDA.

Given that America proceeds with unprecedented revisions to its immunization schedules, a particular individual has surfaced somewhat surprisingly: Høeg, a Danish American physician and public health researcher who initially gained attention by questioning coronavirus vaccinations in the global health crisis and has focused upon alleged deaths following COVID-19 immunization in her short position at the FDA.

Planned Changes to Childhood Immunization Program

Public health authorities were set to unveil sweeping changes to the childhood vaccination calendar in December, synchronizing the US with Denmark’s immunization schedule, according to reports – a major change that would place the US out of step with many the international standard with no evidence for benefit. This reveal has been pushed back until the new year.

In place of the director of the vaccine center, Dr. Høeg is scheduled to present at the event. She was newly appointed acting director of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth person to run the division this calendar year.

A New Direction at the FDA

Høeg's temporary position may indicate a strengthened alliance between the pharmaceutical and vaccine branches as Høeg and Prasad solidify control at the FDA – and it suggests a greater focus upon dismantling long-standing immunizations at the FDA.

The new acting director has often pushed for halting specific childhood immunization guidelines in the US to become more in line with Denmark's approach, a society with comprehensive healthcare and a population about the size of Wisconsin’s.

So far comments, she has persisted in emphasizing on immunizations – traditionally the purview of Dr. Prasad, chief of the FDA’s Center for Biologics Evaluation and Research (CBER) – rather than medication approval.

Doubts Over Background

The appointee has no apparent background in medication creation, oversight or management, which has been customary for past leaders of the Center for Biologics Evaluation and Research. She has worked at the FDA as a key advisor to the commissioner and the vaccine center since March.

“She appears not to have any of the qualifications” for running the drug-regulation department, remarked Jonathan Howard. “She’s never run a clinical trial. She is not versed in leading a large organization. She has no expertise in industry regulation.”

Former commissioners of CBER would “be deeply familiar with regulatory frameworks and the science of pharmaceutical innovation”, said a former acting FDA commissioner. “Clearly, she lacks the type of experience that former directors who led the center have had.”

The drug center has an vast workload at the agency, she stated.

“Everybody just focuses on the new drug program, but the generic program clears thousands of off-brand pharmaceuticals. There’s a biosimilars division, OTC medication office and other areas, and each of these have to be managed,” Woodcock explained. “The responsibility you neglect, that is precisely what that I always told people is going to bite you.”

There is also, a substantial leadership component to the position, which manages more than 5,000 staff members. “It’s a enormous administrative position, if you do it right,” she added.

Official Statement and Controversial Programs

Regarding concerns about Høeg’s fitness for the role and whether this appointment represents greater collaboration among agency officials on vaccines, a spokesperson responded that the “concerns stem from incorrect presumptions”.

“This background matches the responsibilities of her position,” the official said, citing the time Høeg spent counseling the agency head on “pharmaceutical safety and oversight research, including computational safety modeling and shot safety tracking”.

As the temporary head, Dr. Høeg assumes responsibility for the agency head's recently launched fast-track approval initiative, a contentious rapid medication authorization process that reportedly concerned her former heads. “By what process are these drugs being chosen for this fast-track system? Who is making the decisions?” Dr. Howard asked. “There is a lot of secrecy occurring at the regulatory body right now.”

Overall, he said, “the FDA appears to be shifting towards less stringent rules of all drugs, aside from immunizations.”

Documented Past Work on Vaccines

Concerning immunizations, Høeg has a more established, if concerning, past, some experts have noted. She published a study using unverified public submissions to estimate the rate of myocarditis following Covid immunization. She counseled the state of Florida top health official Dr. Joseph Ladapo, who reportedly have changed statistics to imply Covid vaccinations are more dangerous than they are.

Among her “desired changes” for the current administration encompassed changing regulations for recently developed shots and discontinuing “unnecessary” immunizations, she remarked following the vote on a podcast. At the FDA, Høeg has reportedly suggested excluding young men from getting COVID-19 vaccines.

“She is an thorough ideologue who starts off with her preconceived notions and works backwards to accommodate the science in a highly deceptive, fraudulent fashion,” Howard argued.

Gaining Influence and a “Campaign of Retribution”

Dr. Høeg joined other dissenters, {like|